Cell Genesys, Inc. confirmed that a press release issued by Baylor University concerned data from the initial Phase 1/2 clinical trial of Cell Genesys' Gvax lung cancer vaccine trial. The data, which were published in the February 18, 2004 issue of the Journal of the National Cancer Institute, were previously presented in December 2002 at the International Conference on Gene Therapy of Cancer.
Cell Genesys is currently conducting a Phase 2 trial of Gvax lung cancer vaccine to confirm the previous findings using a new semiautomated closed system to produce the vaccine. A second Phase 2 trial, which is expected to be sponsored and partially funded by the Southwest Oncology Group (SWOG), a cooperative clinical trials group of the National Cancer Institute (NCI), will focus on patients with the bronchoalveolar carcinoma (BAC) subtype of non small-cell lung cancer and is expected to be initiated in the second quarter of 2004.